Figure 1.

Primary endpoint of the study EULAR Sjögren’s syndrome disease activity index in the rituximab and disease-modifying anti-rheumatic drug treatment groups. Primary endpoint of the study EULAR Sjögren’s syndrome disease activity index (ESSDAI) in the rituximab (RTX) and the disease-modifying anti-rheumatic drug (DMARD) treatment groups. Bars in the line charts indicate mean ± standard error of the mean. *P < 0.05, comparison between the two treatment arms at the corresponding time point.

Carubbi et al. Arthritis Research & Therapy 2013 15:R172   doi:10.1186/ar4359
Download authors' original image